A new treatment option for individuals living with diabetic complications

Vascular Pharmaceuticals, Inc. is a private biopharmaceutical company working to address the complications of diabetes, specifically diabetic nephropathy. There is a serious unmet need for effective treatments for this patient population, which includes both Type 1 and Type 2 diabetics.

Founded in 2005, the company is advancing our therapeutic candidate, VPI-2960B, through clinical development. Initial data has shown evidence that the novel approach of inhibiting the αVß3 receptor on kidney cells has the potential to halt and even reverse the effect of kidney disease. We are currently enrolling patients in a Phase 2 clinical trial. at more than 40 locations across the United States.

We are committed to bringing safe and effective new treatment options to individuals living with diabetic complications such as nephropathy. The Vascular Pharmaceuticals team, along with our development partner Janssen Biotech, Inc., is dedicated to successfully achieving key milestones and bringing this potential therapeutic breakthrough to commercialization.